Instil Bio Q3 net loss $56.2M; DELTA-1 trial paused; CMO resigns

Instil Bio, Inc.

2022-Q3 EPS reported -$1.31

Q3 net loss $56.2M ($0.43/share); cash & securities $303.3M at Sept 30, down from $454.1M at Dec 31, 2021.
DELTA-1 trial voluntarily paused due to manufacturing contamination; FDA notified; update expected Q1 2023.
DELTA-2 enrollment deferred; first patient dosed with ITIL-306 (CoStAR-TIL) for NSCLC; clinical data expected in 2023.
Dr. Robert Hawkins appointed Head of R&D; Dr. Zachary Roberts resigned as CMO effective Nov 11, 2022.
Cash runway into 2025 expected with planned sale-leaseback of Tarzana manufacturing facility.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Instil Bio, Inc. reported the quarter ended September 30, 2022 results: EPS $ (0.43).

Period: the quarter ended September 30, 2022
EPS: $ (0.43)
Result: reported results

Exact text from the filing

On November 14, 2022, Instil Bio, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended September 30, 2022 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.

View on SEC.gov

Browse all earnings releases →

Instil Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001789769-22-000096

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.